Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

The intestinal epithelium is a highly dynamic barrier that regulates digestion, absorption, immune responses, and communication between the gut microbiota and the nervous system.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...

Ro shares information about how eggs can support weight loss efforts, and the best way to prepare them to meet health goals.

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...